DE69724095D1 - DFMO und Taxol zur Behandlung bzw. Vorbeugung von Brustkrebs - Google Patents
DFMO und Taxol zur Behandlung bzw. Vorbeugung von BrustkrebsInfo
- Publication number
- DE69724095D1 DE69724095D1 DE69724095T DE69724095T DE69724095D1 DE 69724095 D1 DE69724095 D1 DE 69724095D1 DE 69724095 T DE69724095 T DE 69724095T DE 69724095 T DE69724095 T DE 69724095T DE 69724095 D1 DE69724095 D1 DE 69724095D1
- Authority
- DE
- Germany
- Prior art keywords
- dfmo
- breast cancer
- taxol
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 title abstract 6
- 206010006187 Breast cancer Diseases 0.000 title abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 4
- 229930012538 Paclitaxel Natural products 0.000 title abstract 2
- 229960001592 paclitaxel Drugs 0.000 title abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 3
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2783796P | 1996-10-04 | 1996-10-04 | |
| US27837P | 1996-10-04 | ||
| PCT/US1997/018252 WO1998014188A1 (en) | 1996-10-04 | 1997-10-03 | Dfmo and taxol for the treatment or prevention of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69724095D1 true DE69724095D1 (de) | 2003-09-18 |
| DE69724095T2 DE69724095T2 (de) | 2004-05-27 |
Family
ID=21840066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69724095T Expired - Fee Related DE69724095T2 (de) | 1996-10-04 | 1997-10-03 | DFMO und Taxol zur Behandlung bzw. Vorbeugung von Brustkrebs |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0871441B1 (de) |
| AT (1) | ATE246923T1 (de) |
| AU (1) | AU4751597A (de) |
| DE (1) | DE69724095T2 (de) |
| ES (1) | ES2205188T3 (de) |
| WO (1) | WO1998014188A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL195164B1 (pl) * | 1998-09-23 | 2007-08-31 | Lonza Ag | Diastereomeryczne sole (+)-lub (-)-alfa-(difluorometylo) ornityny oraz sposób rozdziału (+)-alfa-(difluorometylo) ornityny |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| JP2002537328A (ja) * | 1999-02-26 | 2002-11-05 | ナプロ バイオセラピューティクス，インコーポレイテッド | ホルモン感受性癌の治療レジメ |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| WO2001068076A2 (en) * | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| US6653351B2 (en) | 2001-08-13 | 2003-11-25 | Board Of Regents, The University Of Texas System | Adjuvant chemotherapy for anaplastic gliomas |
| US7015349B2 (en) | 2003-03-26 | 2006-03-21 | The Gillette Company | Reduction of hair growth |
| JP6508867B2 (ja) | 2013-03-29 | 2019-05-08 | キヤノン株式会社 | 被検体情報取得装置およびその制御方法 |
| CN106265619A (zh) * | 2016-09-29 | 2017-01-04 | 中美（河南）荷美尔肿瘤研究院 | Dfmo或dfmo和姜提取物在制备食管癌和肝癌的预防及临床治疗的药物中的应用 |
| CN117701715A (zh) * | 2023-12-20 | 2024-03-15 | 东莞市第八人民医院（东莞市儿童医院） | Odc1及其抑制剂在乳腺癌他莫昔芬耐药诊断与治疗中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102617A (en) * | 1992-07-23 | 1996-01-19 | Technion Res & Dev Foundation | Method for Assessing Clinical Sensitivity and Multidrug Resistance to Mammalian Cell Anticancer Compounds |
-
1997
- 1997-10-03 EP EP97910042A patent/EP0871441B1/de not_active Expired - Lifetime
- 1997-10-03 AU AU47515/97A patent/AU4751597A/en not_active Abandoned
- 1997-10-03 AT AT97910042T patent/ATE246923T1/de not_active IP Right Cessation
- 1997-10-03 WO PCT/US1997/018252 patent/WO1998014188A1/en active IP Right Grant
- 1997-10-03 DE DE69724095T patent/DE69724095T2/de not_active Expired - Fee Related
- 1997-10-03 ES ES97910042T patent/ES2205188T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2205188T3 (es) | 2004-05-01 |
| DE69724095T2 (de) | 2004-05-27 |
| EP0871441B1 (de) | 2003-08-13 |
| EP0871441A1 (de) | 1998-10-21 |
| WO1998014188A1 (en) | 1998-04-09 |
| AU4751597A (en) | 1998-04-24 |
| ATE246923T1 (de) | 2003-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003960A (es) | Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos. | |
| ATE300292T1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
| DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
| DE69738918D1 (de) | Lipoxinverbindungen und deren Verwendung zur Behandlung der Zellenwucherungsstörung | |
| AU1373499A (en) | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease | |
| ATE319447T1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| DE69332758D1 (de) | Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol | |
| ATE227124T1 (de) | Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung | |
| CA2301032A1 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| DE69724095D1 (de) | DFMO und Taxol zur Behandlung bzw. Vorbeugung von Brustkrebs | |
| DE69715000D1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| ATE219929T1 (de) | Hautbleichende dermatologische und/oder kosmetische zusammensetzung | |
| ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
| DE59605959D1 (de) | Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände | |
| DE60116075D1 (de) | Behandlung von tumoren mit photodynamischer therapie | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| EP1056458A4 (de) | Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen | |
| NZ307601A (en) | Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| ATE311190T1 (de) | Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |